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Abstract
Background: The p.Asn215Ser or p.N215S GLA variant has been associated
with late-onset cardiac variant of Fabry disease.
Methods: To expand on the scarce phenotype data, we analyzed natural history
data from 125 p.N215S patients (66 females, 59 males) enrolled in the Fabry
Registry (NCT00196742) and compared it with data from 401 patients (237
females, 164 males) harboring mutations associated with classic Fabry disease.
We evaluated interventricular septum thickness (IVST), left ventricular posterior
wall thickness (LVPWT), estimated glomerular filtration rate and severe clinical
events.
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Results: In p.N215S males, mildly abnormal mean IVST and LVPWT values
were observed in patients aged 25–34 years, and values gradually increased with
advancing age. Mean values were similar to those of classic males. In p.N215S
females, these abnormalities occurred primarily in patients aged 55–64 years. Sev-
ere clinical events in p.N215S patients were mainly cardiac (males 31%, females
8%) while renal and cerebrovascular events were rare. Renal impairment occurred
in 17% of p.N215S males (mostly in patients aged 65–74 years), and rarely in
females (3%).
Conclusion: p.N215S is a disease-causing mutation with severe clinical manifes-
tations found primarily in the heart. Cardiac involvement may become as severe
as in classic Fabry patients, especially in males.
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1 | INTRODUCTION
Fabry disease (OMIM #301500) is an X-linked lysosomal
storage disorder caused by mutations in the GLA (OMIM
#300644; HGNC 4296; NCBI reference sequence
NM_000169.2) gene encoding enzyme a-galactosidase
(a-Gal, EC 3.2.1.22; Uniprot P06280) (Desnick, Ioannou,
& Eng, 2001; Germain, 2010). Patients with the classic,
severe form of Fabry disease have severely reduced or
absent a-Gal activity leading to progressive lysosomal sub-
strate accumulation [globotriaosylceramide (GL-3) in par-
ticular] in plasma and in a variety of cell types, including
vascular endothelial and smooth muscle cells, podocytes
and other kidney cell types and cardiomyocytes (Germain,
2010). In classically affected male patients, onset of clinical
symptoms occurs in pediatric patients (Hopkin et al., 2008;
Laney et al., 2015; Ramaswami et al., 2006), and life-
threatening complications involving the kidneys, heart and
cerebrovascular system may develop with advancing age
(Germain, 2010; Germain et al., 2013; Ortiz et al., 2008,
2010; Patel et al., 2011; Senechal & Germain, 2003; Sims,
Politei, Banikazemi, & Lee, 2009; Wilcox et al., 2008).
Cardiac events are the most frequently reported cause of
death in the overall Fabry patient population (Mehta et al.,
2009; Waldek, Patel, Banikazemi, Lemay, & Lee, 2009).
In heterozygotes, clinical presentations are more variable
than in male patients and are dependent on multiple factors
including the type of mutation and the X-chromosome
inactivation profile (Echevarria et al., 2016; Germain,
2010; Wilcox et al., 2008).
To date, several predominantly missense mutations
have been reported to be associated with a later-onset car-
diac phenotype of Fabry disease, including p.N215S,
p.M296I, p.R301Q, p.G328R and IVS4+919G>A (Eng,
Resnick-Silverman, Niehaus, Astrin, & Desnick, 1993;
Eng et al., 1994; Germain, 2001, 2010; Germain et al.,
1996; Ishii, Kase, Sakuraba, & Suzuki, 1993; Ishii,
Nakao, Minamikawa-Tachino, Desnick, & Fan, 2002;
Ishii, Sakuraba, & Suzuki, 1992; Ishii et al., 2007; Nakao
et al., 1995; Sachdev et al., 2002; Sakuraba et al., 1990;
von Scheidt et al., 1991; Spada et al., 2006; Yoshitama
et al., 2001). Of these mutations, p.N215S appears to be
the most common mutation in Western countries (personal
communication). It has been reported that cardiac variant
patients may have significant levels of residual a-Gal
activity [2%–20% of normal (Germain, 2001; Ishii et al.,
1993, 2007; Spada et al., 2006)] and generally lack the
early classic symptoms of Fabry disease (e.g., neuropathic
pain, gastrointestinal complaints, angiokeratoma, cornea
verticillata), with manifestations being confined to the
heart predominantly (left ventricular hypertrophy, conduc-
tion disturbances, arrhythmias). These patients generally
present later in life than classic patients (Elleder et al.,
1990; Germain, 2010; Nakao et al., 1995; Patel et al.,
2015; Sachdev et al., 2002; von Scheidt et al., 1991), or
may be diagnosed earlier as a result of neonatal, family
or high-risk population screening initiatives.
The p.Asn215Ser missense mutation [nomenclature rec-
ommended by the Human Genome Variation Society (den
Dunnen et al., 2016); usually referred to as p.N215S]
results from an A-to-G transition at codon 215 in exon 5
of GLA (c.644A>G), with subsequent substitution of a gly-
cosylated asparagine by a serine. Glycosylation at this site
is crucial for the formation of soluble, active enzyme that
can be transported to the lysosome (Ioannou, Zeidner,
Grace, & Desnick, 1998).
The purpose of our study was to determine the pheno-
typic characteristics of patients with the Fabry p.N215S
mutation, and to compare them with the characteristics of
patients harboring mutations associated with classic Fabry
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disease followed at the same clinical centers providing spe-
cialized care to the p.N215S patients.
2 | PATIENTS AND METHODS
2.1 | Patients
This study includes male and female patients enrolled in
the Fabry Registry (age range: 0.5–72.5 years at first
assessment) diagnosed with Fabry disease and harboring
the p.N215S mutation. All patients were from 10 interna-
tional Fabry Registry sites that had contributed clinical data
for a minimum of six p.N215S patients, and had received
specialized care supervised by one of the authors (D.P.G.,
E.B., F.C., S.P.S./D.A.L., A.L., L.M., K.N., F.P., S.P.S.,
C.W., A.J.).
2.2 | Outcomes
We analyzed natural history data (i.e., obtained before initia-
tion of enzyme replacement therapy [ERT], if indicated)
including left ventricular posterior wall thickness (LVPWT),
interventricular septum thickness (IVST) and estimated
glomerular filtration rate (eGFR) (bedside Schwartz equa-
tion if <18 years of age, Chronic Kidney Disease Epide-
miology Collaboration [CKD-EPI] equation if ≥18 years of
age). The first values entered in the Fabry Registry were
used for analysis. We also evaluated severe clinical events
including: (1) Cardiac events: angina pectoris, arrhythmia,
congestive heart failure, myocardial infarction, implantation
of cardiac devices, significant cardiac procedure; (2) Renal
events: first occurrence of either the initiation of chronic
dialysis (>40 days) or renal transplantation; (3) Cerebrovas-
cular events: hemorrhagic or ischemic stroke; and (4) Death.
The first severe clinical event that occurred during natural
history follow-up and time to first clinical event was ana-
lyzed for each of the event types. We analyzed electrocar-
diogram (ECG) data separately to further define arrhythmia
subtypes. We compared clinical data from p.N215S patients
to Fabry Registry data from patients harboring GLA muta-
tions associated with classic Fabry phenotype followed
at the same clinical centers. The mutation classification
“classic Fabry disease” for these patients was verified using
data from the Fabry-database.org mutation database (Fabry
disease mutation database, 2017). The final list of classic
mutations (Table S1) was reviewed and approved by a
senior geneticist experienced in the molecular diagnosis and
management of Fabry patients (D.P.G).
2.3 | Statistical methods
We analyzed IVST, LVPWT and eGFR data by age group:
<25 years; 25–34 years; 35–44 years; 45–54 years;
55–64 years; and 65–74 years. Kaplan–Meier models
depicting estimates of time to first reported event during
natural history follow-up were performed for p.N215S and
classic Fabry patients of both genders. We used descriptive
statistics to characterize the individuals within the respec-
tive age groups. Statistical analyses were performed using
SAS statistical software V.9.2 (SAS Institute Inc., Cary,
NC, USA).
2.4 | Fabry Registry
The Fabry Registry (NCT00196742; sponsor: Sanofi Gen-
zyme) is a multicenter, international, longitudinal, observa-
tional program designed to track the natural history and
outcomes of patients with Fabry disease (Fabry Registry
website, 2017). Patient and investigator participation is vol-
untary. Each independent site is responsible for obtaining
patients’ informed written consent to submit their health
information to the Registry, and to use and disclose this
information in aggregate analyses. The Registry protocol,
informed consent form and any locally required authoriza-
tion documents to send patient information to the Registry
are reviewed and approved by the local fully constituted
Institutional Review Board (IRB) or Independent Ethics
Committee (IEC) unless the site provides the Registry with
documentation that approval is not required or has been
waived by a particular IRB/IEC.
3 | RESULTS
3.1 | Patient demographics
Data from 125 patients (59 males, 66 females) with the
p.N215S genotype from the 10 centers were available in
the Fabry Registry; the total number of p.N215S patients
enrolled worldwide was 231 (105 males, 126 females).
Mean age (range) at first assessment of IVST, LVPWT and
eGFR in p.N215S males was 49.1 (8.7–72) years, 50.6
(8.7–71.4) years and 51.9 (8.7–72.5) years, respectively.
For p.N215S females, mean age (range) was 41 (0.5–69.3)
years for IVST and LVPWT, and 41 (5.8–69.2) years for
eGFR. These data were compared to data from 401 patients
(164 males, 237 females) harboring classic Fabry disease
mutations followed at the same centers.
3.2 | IVST and LVPWT
For p.N215S males, overall, 88% and 74% had an abnor-
mal value [≥11 mm (Lang et al., 2015)] for IVST and
LVPWT, respectively, at first assessment during natural
history follow-up. Mean (standard deviation [SD]) IVST
and LVPWT values were first mildly abnormal in the 25–
34-year age group with values of 13.4 (1.8) mm
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(Figure 1a) and 11.0 (1.4) mm (Figure 1c), respectively;
mean values gradually increased with advancing age to
severely abnormal mean values of 22.9 (8.0) (Figure 1a)
and 16.5 (3.9) mm (Figure 1c), respectively, in the 65–74-
year age group.
For classic male patients, mean (SD) IVST and LVPWT
values were also first mildly abnormal for the 25–34-year
age group, with values of 11.0 (2.2) mm (Figure 1a) and
11.1 (2.6) mm (Figure 1c), respectively; values increased
with advancing age to maximum moderately abnormal
mean values of 15.8 (4.6) mm (Figure 1a) and 14.7 (3.1)
mm (Figure 1c), respectively, in the 45–54-year age group.
No classic male patients reported their first natural history
assessment at age 65–74 years.
For p.N215S females, overall, 49% and 34% of the
females had an abnormal value [≥10 mm (Lang et al.,
2015)] for IVST and LVPWT, respectively, at first assess-
ment. Mean (SD) IVST was first mildly abnormal in the
45–54-year age group [10.2 (1.3) mm (Figure 1b)] and
mean (SD) LVPWT was mildly abnormal in the 55–64-
year age group [10.2 (1.1) mm (Figure 1d)], and remained
mildly abnormal with advancing age.
For classic female patients, IVST and LVPWT were
abnormal from age 45–54 years onward (Figure 1b,d).
IVST and LVPWT reached a maximum mean (SD) value
in patients aged 65–74 years [16.5 (5.6) mm (severely
abnormal)] and 55–64 years [12.3 (1.9) mm (mildly abnor-
mal)], respectively.
3.3 | eGFR
For p.N215S patients, overall, 17% of males and 3% of
females had an eGFR value at first assessment during natu-
ral history follow-up of <60 ml/min/1.73 m2, suggestive of
chronic kidney disease. For both genders, p.N215S
patients’ mean eGFR values remained >60 ml/min/1.73 m2
for all age groups except males aged 65–74 years [mean
eGFR (SD) 54.1 (21.5) ml/min/1.73 m2] (Figure 2a).
For classic male patients, mean eGFR was first abnor-
mal in the 55–64-year age group [mean eGFR (SD) 56.8
(32.0) ml/min/1.73 m2; there were no males with first
assessments at age 65–74 years], whereas for classic
females, mean eGFR values were above the lower limit of
normal in all age groups (Figure 2b).
FIGURE 1 Interventricular septum thickness (IVST) and left ventricular posterior wall thickness (LVPWT) values at first assessment during
natural history follow-up. IVST values are shown for male (a) and female (b) p.N215S (blue) and classic (red) patients. LVPWT data are shown
for male (c) and female (d) p.N215S (blue) and classic (red) patients. Ranges in males: normal, 6–10 mm; mildly abnormal, 11–13 mm;
moderately abnormal, 14–16 mm; severely abnormal, >16 mm. Ranges in females: normal, 6–9 mm; mildly abnormal, 10–12 mm; moderately
abnormal, 13–15 mm; severely abnormal, >15 mm (Lang et al., 2015). Data are presented as mean and SD
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3.4 | Severe clinical events
First severe clinical events in p.N215S males (32%)
occurred at a mean age of 52.4 years, approximately
14 years later as compared to classic male patients (33%),
whereas in p.N215S females (9%) and classic female
patients (20%) first events occurred at a similar mean age
(approximately 50 years) (Table 1).
p.N215S males primarily had cardiac events (31%), with
arrhythmia and significant cardiac procedure being most
prevalent. No p.N215S males reported angina pectoris
whereas 5% of p.N215S females reported this type of
event; in total, 8% of p.N215S females reported a cardiac
event (Table 1).
Only one male p.N215S patient had a cerebrovascular
event (ischemic stroke, age 54 years, no atrial fibrillation),
and only one female p.N215S patient had a renal event
(dialysis, age 45 years) as first severe event (Table 1). The
analysis of severe events included those events that
occurred as first event. It should be noted that four
p.N215S patients experienced a renal event not documented
as first severe event during natural history follow-up (i.e.,
kidney transplant in one 54-year-old male; dialysis in one
39-year-old male, followed by kidney transplant at age
FIGURE 2 Estimated glomerular filtration rate (eGFR) values at first assessment during natural history follow-up. eGFR values are shown
for male (a) and female (b) p.N215S (blue) and classic (red) patients. Values <60 ml/min/1.73 m2 indicate the presence of chronic kidney
disease. Data are presented as mean and SD
TABLE 1 Severe clinical events reported as first clinical event in p.N215S and classic Fabry disease patients from the clinical centers
participating in the study
Severe clinical events
p.N215S males
(n = 59)
Classic males
(n = 164)
p.N215S females
(n = 66)
Classic females
(n = 237)
n (%)
Mean age
(SD), years n (%)
Mean age
(SD), years n (%)
Mean age
(SD), years n (%)
Mean age
(SD), years
Any event 19 (32) 52.4 (11.8) 54 (33) 38.3 (10.9) 6 (9) 50.2 (11.6) 47 (20) 49.2 (13.6)
Cardiac event 18 (31) 52.3 (12.1) 34 (21) 43.3 (10.6) 5 (8) 51.1 (12.8) 36 (15) 50.2 (13.6)
Angina pectoris - - 9 (5) - 3 (5) - 14 (6) -
Arrhythmia 10 (17) - 13 (8) - 1 (2) - 14 (6) -
Congestive heart failure 1 (2) - 4 (2) - - - - -
Myocardial infarction 1 (2) - 2 (1) - - - - -
Significant cardiac procedure 6 (10) - 6 (4) - 1 (2) - 8 (3) -
Renal event - - 25 (15) 36.9 (11.3) 1 (2) 45.0 1 (<1) 41.0
Chronic dialysis - - 23 (14) - - - - -
Transplant - - 2 (1) - 1 (2) - 1 (<1) -
Cerebrovascular event 1 (2) 54.1 12 (7) 34.8 (8.8) - - 15 (6) 47.2 (13.7)
Hemorrhagic stroke - - 2 (1) - - - - -
Ischemic stroke 1 (2) - 10 (6) - - - 15 (6) -
Death - - 2 (1) 47.0 (7.7) - - 1 (<1) 66
SD, standard deviation.
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43 years; and dialysis in two females aged 51 and
63 years) for a total of 5/125 (4%) renal events as first
event or during follow-up, all before age 65 years.
Cardiac events in classic males were less frequent as com-
pared to p.N215S males (21% vs. 31%) (Table 1), with
arrhythmia and angina pectoris being most common. Cardiac
events occurred at younger ages in classic males compared
to p.N215S males (mean age 43 years vs. 52 years). Mean
age of cardiac events was similar for classic females and
p.N215S females (approximately 50 years).
Substantially more noncardiac first events occurred in
classic males compared to p.N215S males [i.e., renal events
(15%) and cerebrovascular events (7%), with ischemic
stroke being most prevalent (6%)]. Ischemic stroke
occurred in 6% of classic females, but did not occur in
p.N215S females (Table 1).
No deaths were reported in p.N215S patients as first
severe clinical event, whereas three classic patients died
(Table 1).
Separate analysis of arrhythmia data from ECGs showed
that p.N215S males primarily had sinus bradycardia (7%),
atrial fibrillation (4%) and other rhythm abnormalities (4%).
Sinus bradycardia was the most prevalent type of arrhyth-
mia in p.N215S females (7%). Arrhythmia subtypes in clas-
sic patients did not substantially differ as compared to
p.N215S patients.
Kaplan–Meier models depicting estimates of time to
first reported severe clinical event (any, cardiac, cerebro-
vascular, renal) during natural history follow-up are shown
for p.N215S and classic patients of both genders (Fig-
ure 3a,b). For male p.N215S patients, cardiac events started
to occur in the fourth decade of life, similar to classic
males, whereas in female p.N215S patients, cardiac events
were less common and appeared to first occur in the sixth
decade of life.
3.5 | Patients initiating ERT
Among p.N215S patients, 76% of males and 21% of
females were initiated on ERT, at a mean age (SD) of 49.1
(15.7) years and 43.6 (14.2) years, respectively. Among
classic patients, 92% of males and 46% of females were
initiated on ERT, at a mean age (SD) of 36.6 (13.1) years
and 46.3 (13.0) years, respectively.
4 | DISCUSSION
The p.N215S missense mutation has been labeled as a
later-onset cardiac phenotype of Fabry disease (Eng et al.,
1993, 1994; Germain, 2010; Germain et al., 1996; Ishii
et al., 1992, 2002; Nakao et al., 1995; Patel et al., 2015;
von Scheidt et al., 1991); however, published phenotypic
data are still scarce. Three publications reported clinical
findings in cohorts of patients with this mutation, but
lacked detailed gender-specific clinical information (Arends
et al., 2017; Havranek, Linhart, Urbanova, & Ramaswami,
2013; Patel et al., 2015). In this Fabry Registry study, we
analyzed data from clinical descriptions of 59 male and 66
female p.N215S patients, making it the largest cohort
reported to date.
Our study confirms that p.N215S is a disease-causing
Fabry mutation with severe clinical manifestations essen-
tially limited to the heart until late adulthood, especially in
males. The majority of p.N215S males had mildly abnor-
mal IVST and LVPWT values at first assessment, progress-
ing, from age 25–34 years onward, to severely abnormal
mean values in elderly patients, and almost all first severe
clinical events reported were cardiac (31% of patients).
A minority of p.N215S males had a slightly abnormal
eGFR value at first assessment, most frequently among
those aged 65–74 years. Renal and cerebrovascular events
reported as first events were extremely rare. In p.N215S
heterozygotes, IVST, LVPWT and eGFR abnormalities
were rare across all age groups with exception of IVST,
which was abnormal in patients aged 55–64 years. Cardiac
events occurred in 8% of female p.N215S patients. No
deaths were reported during natural history follow-up in
the p.N215S population.
Mean IVST and LVPWT values in p.N215S patients were
not distinctly different from those in patients harboring muta-
tions associated with classic Fabry disease with the exception
that classic females in the oldest age groups seemed more
affected – no classic males had first natural history assess-
ments at age 65–74 years. The frequency of cardiac first
events was higher in p.N215S males than in classic males
(31% vs. 21%); however, events occurred at a later age (52.3
vs. 43.3 years). The higher rate of renal events in classic
males (15%) may have contributed to the earlier occurrence of
cardiac events given the well-established association between
renal failure and greater cardiovascular risk (Ortiz et al.,
2014). Cardiac events were less frequent in p.N215S females
than in classic females (8% vs. 15%) but occurred at a similar
mean age. Tissue biopsies or autopsy studies of cardiac phe-
notypes of Fabry disease have revealed GL-3 accumulation in
cardiomyocytes but not in the vasculature of the heart, or
other tissues (Desnick et al., 2001; Elleder et al., 1990; von
Scheidt et al., 1991), suggesting that residual levels of a-Gal
can limit GL-3 accumulation in the endothelium and, theoreti-
cally, the risk of Fabry-related angina pectoris or myocardial
infarction (Mayes, Cray, Dell, Scheerer, & Sifers, 1982).
In the current study, 17% of p.N215S males (primarily
patients aged 65–74 years) had an abnormal eGFR value at
first assessment; mean eGFR in classic males was abnormal
a decade earlier. No renal events were reported as first
event for male p.N215S patients, and these events occurred
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FIGURE 3 Kaplan–Meier curves depicting estimates of time to first severe clinical event. Data are shown for any clinical events, cardiac
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very rarely during natural history follow-up in all female
patients. In total, five patients (three females) required renal
replacement therapy during the course of their disease (not
reported as first severe event for four patients). This illus-
trates that, although the p.N215S variant is primarily car-
diac in nature, a minority of p.N215S patients may develop
renal impairment later in life, which may or may not be
secondary to cardiac compromise. In addition, in patients
with kidney function abnormalities, exclusion of non-
Fabry-related medical conditions causing kidney disease
(e.g., diabetes, heart failure, hypertension, primary
glomerulonephritis, collagen polymorphisms) as well as
identification of risk factors, such as obesity, hypercholes-
terolemia, smoking habits, alcohol consumption, nephro-
toxic drugs (i.e., anticoagulants, diuretics) and contrast
media, is warranted. Moreover, renal function declines with
age in the normal adult population; the reported rate of loss
of eGFR, beginning at age 40 years, is 1 ml/min/1.73 m2/
year (Lindeman, Tobin, & Shock, 1985). GFR and albu-
minuria/proteinuria should be monitored regularly once an
abnormality has been detected. Regarding the possibility of
Fabry-related primary kidney disease, a single case of a
75-year-old p.N215S male with proteinuria, mildly
decreased renal function attributed to arteriosclerosis, and
GL-3 accumulation mostly limited to podocytes (absent
from most other renal cell types, including vascular
endothelium) has been reported to date (Meehan, Junsanto,
Rydel, & Desnick, 2004).
The observation that cardiac involvement in p.N215S
patients can become as severe as, and sometimes even more
severe than, in patients with classic Fabry mutations may be
due to silent progression of cardiac disease until the (often
delayed) diagnosis and subsequent enrollment in the Fabry
Registry. Characteristic early-onset Fabry symptoms
observed in classic patients (e.g., neuropathic pain, angio-
keratoma, cornea verticillata) are reportedly rare in p.N215S
patients, but may occur (Arends et al., 2017). Thus, early
symptoms generally cannot alert the clinician to a possible
diagnosis of Fabry disease and trigger therapeutic interven-
tion. Fabry disease screening, through evaluation of a-Gal
activity in plasma/leukocytes and genetic analysis in individ-
uals with hypertrophic cardiomyopathy aged ≥30 years, may
identify these patients. However, the presence of a sarcom-
eric or a transthyretin mutation should also be ruled out.
Stroke as first severe clinical event occurred in only one
male p.N215S patient without evidence of atrial fibrillation
on ECGs. To rule out silent episodic atrial fibrillation as
cardioembolic cause of stroke, ECG-Holter prolonged mon-
itoring or loop recorders may be useful tools.
The substitution of a serine for an asparagine at codon
215 of a-Gal can have major implications. When wild-type
a-Gal enzyme is expressed in Chinese hamster ovary or
human cells, the N-linked glycan attached at N215 is either
high mannose, hybrid or complex (Lee et al., 2003). This
glycan can be used for the trafficking of a-Gal to the lyso-
some. The p.N215S mutation lacks the (large) N-linked
glycan attachment site at 215 (Figure 4). These N-linked
glycans can help stabilize glycoprotein structures through
protein–glycan interactions and have critical roles in the
folding and trafficking of macromolecules (Hebert, Lam-
riben, Powers, & Kelly, 2014). However, the crystal struc-
ture of a-Gal shows that the N215 carbohydrate extends
away from the surface of the protein. As seen in Figure 4,
the smaller serine can be accommodated easily by the
structure of a-Gal. Thus, the loss of the glycan at 215
could lead to loss of interactions with macromolecular
chaperones such as calnexin and calreticulin. Additionally,
because the N-linked glycan helps the a-Gal molecule traf-
fic to the lysosome, loss of the glycan at 215 may affect
the subcellular distribution of the enzyme. All in all, the
p.N215S mutation appears to have altered folding and traf-
ficking of a-Gal to the lysosome. However, the reason why
patients harboring the p.N215S mutation show almost no
renal involvement remains to be ascertained.
This study has some limitations. Our analysis included
patients’ first renal and cardiac assessments during natural
history follow-up, as recorded in the Fabry Registry. The
start of natural history follow-up varies for individual
patients and is dependent on the age at definitive diagnosis
of Fabry disease, which in turn depends on the severity of
symptoms and the method used to establish diagnosis
(clinical suspicion, family screening, high-risk-population
screening, neonatal screening). Data may not have been
entered retrospectively for enrolled patients, and given that
newly diagnosed severe classic patients may be initiated on
ERT soon after diagnosis without all recommended assess-
ments having been performed, natural history data may be
incomplete. This also applies to documentation of early dis-
ease symptoms in p.N215S patients diagnosed well into
adulthood, which may not be fully available in the Fabry
Registry. Furthermore, classic patients are more likely to
be initiated on ERT and at a younger age (particularly male
patients). Therefore, the rate of severe clinical events dur-
ing natural history follow-up should be interpreted with
caution. Cardiac or renal biopsy data from p.N215S
patients were not available in the Fabry Registry. Cardio-
vascular risk factors including the extent of myocardial
fibrosis, hypertension, hypercholesterolemia, obesity,
tobacco use, lack of physical activity, and diabetes have
not been assessed in this analysis. Although unlikely,
Fabry mutations currently categorized as classic in the
Fabry-database.org mutation database may eventually prove
to be associated with a later-onset phenotype based on
evolving knowledge about the mutation’s phenotypic char-
acteristics. Incomplete data sets for left ventricular mass
(indexed), urine protein-to-creatinine ratio, Fabry disease
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biomarkers [e.g. globotriaosylceramide (GL-3), globotriao-
sylsphingosine (lyso-GL-3)], and chronic white matter
hyperintensities on brain magnetic resonance imaging pre-
cluded meaningful analysis of these parameters. Data from
patients were analyzed per age category and, therefore,
these analyses are cross-sectional rather than longitudinal.
Not all p.N215S Fabry disease patients have been diag-
nosed and enrolled in the Fabry Registry. This may be par-
ticularly applicable to female heterozygotes. Relatively few
females were included in this analysis, since, given the X-
linked inheritance pattern, the female-to-male ratio should
approach 2:1 (Germain & Jurca-Simina, 2018). A patient
selection bias toward the inclusion of more severely
affected patients cannot be excluded, whereas asymp-
tomatic patients may not have come to medical attention.
The Fabry Registry contains observational data of Fabry
patients only. It is not a prospective clinical trial, and data
interpretation is limited by the lack of an appropriately
matched control group.
5 | CONCLUSIONS
This study analyzed the clinical characteristics of 59 male
and 66 female Fabry patients with the p.N215S mutation
and represents the largest sample size with this type of data
reported to date. The data confirm that p.N215S is a dis-
ease-causing Fabry mutation. Severe clinical manifestations
are found primarily in the heart until late adulthood and,
particularly in male patients, cardiac involvement appears
to be progressive and may become as severe as (or occa-
sionally more severe than) in patients with classic Fabry
disease. Renal impairment was observed in few male
p.N215S patients later in life and was uncommon in
females. If observed, monitoring of renal function (GFR
and albuminuria/proteinuria) and exclusion of other Fabry-
unrelated causes of renal insufficiency are warranted. Once
abnormalities have been observed in patients with the
Fabry p.N215S genotype, early diagnosis and close moni-
toring of cardiac status is important because Fabry-specific
therapeutic intervention and treatment of cardiovascular risk
factors may be indicated, as well as cascade family screen-
ing for early diagnosis of family members.
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